In summary, the observations from this and previous papers suggest that GITR-targeted therapies could be used, in combination with other approaches, to restore function in exhausted CD8+ T cells during chronic viral infection without boosting immunopathology. This evidence concerns the gene CD8A and viral infectious disease.